SPECTRAGENETICS

Biotech · Private

Miniaturized multiplexed assay system that detects and quantifies GPCR receptor downregulation, desensitization, and resensitization across large panels of human GPCRs in parallel

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$4.1M
Federal grants
$4.1M
9 awards · 2016–2024
Rank in peer group#19 of 42
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$11K
2 awards · Veterans Affairs
Rank in Biotech#381 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20102012201420162018202020222024FEDERAL ↑EQUITY ↓Cumulative $4.1M$432K$425K$711K$661K$308K$893K
2010201420182022FEDERAL ↑EQUITY ↓Cumulative $4.1M$432K$711K$661K$893K

Latest events

  • Federal grantHealth and Human S · Phase II · Highly Multiplexed Cell-Based GPCR Assay.$893K
  • Federal grantHealth and Human S · Phase II · Highly Multiplexed Cell-Based GPCR Assay.$308K
  • Federal grantHealth and Human S · Phase II · Highly Multiplexed Cell-Based GPCR Assay.$661K
  • Federal grantHealth and Human S · Phase II · Highly Multiplexed Cell-Based GPCR Assay.$711K
  • Federal grantHealth and Human S · Phase I · Highly multiplexed live-cell GPCR arrays for drug discovery in glioma.$223K
  • Federal grantHealth and Human S · Phase II · Highly Multiplexed Cell-Based GPCR Assay.$425K
  • Federal grantHealth and Human S · Phase II · Highly Multiplexed Cell-Based GPCR Assay.$432K
Show 4 earlier federal awards
  • Federal grantHealth and Human S · Phase I · Scalable Multiplexed Microarray Assay For Receptor Downregulation$231K
  • Federal grantHealth and Human S · Phase I · Scalable Multiplexed Microarray Assay For Receptor Downregulation$214K
  • Federal contractVeterans Affairs · Reporter Fosmid For Alternative Splicing Of Human IL4$5K
  • Federal contractVeterans Affairs · DH5A Satb Custom Engineered Fosmid Gene, S, Etc. Used In Research$6K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 42 peers

Line = median

Biotech · Instrument

  • Federal grants#19 · top 45%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .